The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.
The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.
The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.
As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.
The revenue increase was driven in part by surging direct sales of the firm's diagnostic test cartridges and instruments in Europe, the Middle East, and Asia.
Revenues fell as an increase in sales of test cartridges for its Unyvero molecular diagnostic instrument was offset by a decline in system and service sales.
The company said it will use the proceeds for the US commercial launch of its Unyvero molecular diagnostic platform, among other things.
The test cartridge runs on the company's Unyvero platform and covers 103 diagnostic targets for various pathogens and markers of antibiotic resistance.
The firm also received approval from the Singapore Health Sciences Authority to market the Unyvero blood culture cartridges.
The PCR-based cartridge is designed to detect 21 pneumonia pathogens and 19 genetic markers of antibiotic resistance, and runs on the company's Unyvero system.